Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 8/20 | 0.54 |
| ▸ | ADRA1D | P25100 | 7/20 | 0.54 |
| ▸ | ADRA1B | P35368 | 7/20 | 0.54 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.54 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.54 |
| ▸ | CCR2 | P41597 | 4/20 | 0.50 |
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.41 |
| ▸ | ACLY | P53396 | 3/20 | 0.40 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5273090 | 0.86 | CCR2 (0.48) | ADRA1AADRA1DADRA1BADRA2CADRA2A | |
| SCHEMBL1748256 | 0.74 | HTR6 (0.54) | ADRA1AADRA1DADRA1BADRA2CADRA2A | |
| SCHEMBL1748401 | 0.74 | CCR2 (0.49) | ADRA1AADRA1DADRA1BADRA2CADRA2A | |
| Hydrochloric Acid SCHEMBL1748665 | 0.74 | HTR6 (0.53) | ADRA1AADRA1DADRA1BADRA2CADRA2A | |
| SCHEMBL5021178 | 0.72 | MAPT (0.51) | — | |
| SCHEMBL5283022 | 0.72 | MAPT (0.45) | ADRA1AADRA1DADRA1BADRA2CACLY | |
| SCHEMBL5275585 | 0.70 | ADRA1D (0.43) | ADRA1AADRA1DADRA1BADRA2CADRA2A | |
| SCHEMBL1748251 | 0.70 | ACLY (0.50) | ACLYCISD1 | |
| SCHEMBL5612493 | 0.70 | ADRA1A (1.00) | ADRA1AADRA1DADRA1BADRA2CADRA2A | |
| SCHEMBL644001 | 0.68 | CCR2 (0.50) | ADRA1AADRA1DADRA1BADRA2CADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8604021-B2 | Substituted arylamine compounds and methods of treatment | BECKER OREN (IL) | 2013-12-10 | — | — | US | disclosed |
| US-20120115850-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS AND METHODS OF TREATMENT | BECKER OREN (IL) | 2012-05-10 | — | — | US | disclosed |
| US-20120115850-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS AND METHODS OF TREATMENT | BECKER OREN (IL) | 2012-05-10 | — | — | US | disclosed |
| US-20120115850-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS AND METHODS OF TREATMENT | BECKER OREN (IL) | 2012-05-10 | — | — | US | disclosed |
| US-7968538-B2 | Substituted arylamine compounds and methods of treatment | GALENEA CORP. (US) | 2011-06-28 | — | — | US | disclosed |
| US-7968538-B2 | Substituted arylamine compounds and methods of treatment | GALENEA CORP. (US) | 2011-06-28 | — | — | US | disclosed |
| US-7968538-B2 | Substituted arylamine compounds and methods of treatment | GALENEA CORP. (US) | 2011-06-28 | — | — | US | disclosed |
| US-20060205737-A1 | Substituted arylamine compounds and methods of treatment | GALENEA CORPORATION | 2006-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115850-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS AND METHODS OF TREATMENT | HTR6, HTR2A, HTR3B | ADRA1A 67/4885ADRA1D 75/4885ADRA1B 47/4885 |
| US-20060205737-A1 | Substituted arylamine compounds and methods of treatment | HTR6, HTR2A, HTR3B | ADRA1A 67/4885ADRA1D 75/4885ADRA1B 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.